Foundayo™ (orforglipron), a new oral GLP-1 pill for weight loss developed by Eli Lilly and Company, is now available in the U.S. This medication is designed for adults with obesity or overweight individuals with weight-related medical issues, and it can be taken once daily without food or water restrictions. Foundayo is a small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that has shown promising results in clinical trials, helping individuals lose excess body weight and keep it off. The pill is available via LillyDirect® and telehealth providers, with plans to expand to U.S. retail pharmacies.
In the ATTAIN clinical trial program, Foundayo demonstrated its effectiveness. Participants taking the highest dose of Foundayo and adhering to the treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with a placebo. Across all doses, Foundayo led to significant reductions in cardiovascular risk markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
However, it's important to note that Foundayo may cause side effects such as nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, swollen belly, fatigue, belching, heartburn, gas, and hair loss. More serious potential risks include thyroid tumors, including thyroid cancer, and low blood sugar. Patients should be aware of symptoms like a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath, and seek medical attention if experienced.
Foundayo is priced at $149 per month for self-pay patients, but eligible individuals with commercial coverage can pay as little as $25 per month. Additionally, Medicare Part D beneficiaries may pay $50 per month. The medication is not recommended for use with other GLP-1 receptor agonist medicines, and it is not suitable for children.
Despite its benefits, Foundayo's availability is limited due to insurance coverage issues. Only half of Americans with employer-sponsored insurance have coverage for obesity management medications, highlighting the need for improved access and affordability in obesity treatment.
